ROSE Diagnostics closes funding round with $2.3M Reg D financing

Carlsbad, CA - May 14th 2025

ROSE Diagnostics Inc., an innovative leader in rapid cancer diagnostics, today announced the successful completion of its second financing round, securing $2.3 million. This milestone marks a significant step forward in the company's mission to commercialize its impactful line of point-of-care products for cancer biopsy verifications.

The private, Regulation D offering, attracted a mix of new and previous round investors including industry veterans and entrepreneurs with successful exits, signaling broad interest and confidence in ROSE Diagnostics' vision. With the successful close of this round, the company is well-positioned to complete their clinical studies and continue on the path to FDA regulation.

The funds raised will be used to accelerate ROSE Diagnostics' growth, including investments in product development and the completion of their clinical trials. The company has already achieved great strides in improving their verifi LUNG Test product system, positioning itself for FDA approval and commercialization in the future.

For further inquiries, please contact: info@rose-dx.com.